Atorvastatin side effects: a doctor's complete guide

In my experience prescribing atorvastatin, the majority of patients tolerate it well. According to the BNF, common side effects (affecting 1 in 10 to 1 in 100 patients) include:

• Muscle aches (myalgia): the most frequently discussed side effect, typically presenting as generalised muscle discomfort or stiffness
• Headache: usually mild and resolves within the first few weeks
• Nasopharyngitis: sore throat and nasal congestion are commonly reported in clinical trials
• Gastrointestinal disturbance: nausea, diarrhoea, constipation, flatulence and dyspepsia
• Joint pain (arthralgia): particularly in larger joints such as knees and hips
• Raised blood glucose: a class effect of statins recognised by the MHRA

It is important to note that in large clinical trials, many of these symptoms occurred at similar rates in both the treatment and placebo groups.

The ASCOT-LLA trial, for example, showed no significant difference in muscle symptom reporting between atorvastatin and placebo during the blinded phase, though symptoms increased in the atorvastatin group during the unblinded extension.

I always advise patients to give atorvastatin a fair trial of at least 4 to 6 weeks before concluding that side effects are intolerable. Many initial symptoms settle with time.

Muscle symptoms are by far the most common reason patients ask to stop atorvastatin.

However, it is essential to distinguish between different types of muscle problems, as they carry very different levels of clinical significance.

Myalgia (muscle pain without CK elevation):

This is the commonest muscle complaint, affecting approximately 5 to 10% of patients in clinical practice.

Symptoms include aching, heaviness, weakness or cramping, typically affecting the thighs, calves and upper arms. CK (creatine kinase) levels are normal.

In most cases, the symptoms are tolerable and do not require treatment discontinuation.

Myositis (muscle pain with elevated CK):

This is less common, affecting fewer than 1 in 1,000 patients. CK levels are elevated above 5 times the upper limit of normal, indicating muscle damage.

Treatment should be interrupted and CK monitored.

Rhabdomyolysis:

This is an extremely rare but life-threatening condition (fewer than 1 in 10,000 patients) involving severe muscle breakdown with CK levels exceeding 10 times the upper limit of normal.

Symptoms include severe pain, dark (cola-coloured) urine, weakness and potentially acute kidney injury. This requires immediate hospital admission.

Risk factors for muscle problems:

• Higher doses (80 mg carries greater risk than 20 mg)
• Advanced age (over 70)
• Female sex
• Small body frame
• Hypothyroidism (untreated)
• Concurrent use of interacting drugs (fibrates, ciclosporin, macrolide antibiotics)
• Renal impairment
• Excessive alcohol intake

If you develop unexplained muscle pain, weakness or dark urine, stop atorvastatin and seek medical advice promptly. Your GP will check your CK level to determine the severity.

Atorvastatin is metabolised in the liver, and transient elevations in liver enzymes (ALT and AST) are a recognised side effect.

What the evidence shows:

• Liver enzyme elevations above 3 times the upper limit of normal occur in approximately 0.5 to 1% of patients
• These elevations are usually asymptomatic and often resolve even with continued treatment
• Clinically significant liver injury (hepatitis, liver failure) is extremely rare

Current monitoring recommendations:

NICE CG181 recommends:

• Liver function tests before starting atorvastatin
• Repeat LFTs at 3 months and 12 months after starting treatment
• Routine LFT monitoring thereafter is no longer recommended in the absence of symptoms

The BNF advises that atorvastatin should be used with caution in patients with a history of liver disease.

It is contraindicated in patients with active liver disease or unexplained persistent elevations in serum transaminases.

When to be concerned:

Contact your GP if you develop:

• Unexplained fatigue, malaise or weakness
• Loss of appetite, nausea or vomiting
• Dark urine or pale stools
• Yellowing of the skin or eyes (jaundice)

In my practice, I reassure patients that serious liver problems with atorvastatin are exceptionally rare.

The cardiovascular benefits of statin therapy far outweigh the small risk of liver enzyme changes in the vast majority of patients.

The MHRA issued a Drug Safety Update in 2012 acknowledging that statin therapy, including atorvastatin, is associated with a small increase in the risk of developing type 2 diabetes.

The evidence in context:

• A meta-analysis of 13 statin trials found that statin therapy was associated with a 9% relative increase in diabetes risk
• In absolute terms, this translates to approximately 1 additional case of diabetes per 255 patients treated with a statin for 4 years
• The risk is slightly higher with higher-intensity statins (including atorvastatin 80 mg)
• Patients who develop diabetes on statins tend to have pre-existing risk factors (obesity, impaired fasting glucose, metabolic syndrome)

The benefit-risk balance:

NICE CG181 states clearly that the cardiovascular benefits of statin therapy outweigh the small increased risk of diabetes. To illustrate:

• For every 255 patients treated, statins prevent approximately 5.4 major cardiovascular events while causing 1 additional case of diabetes
• The net clinical benefit remains strongly in favour of treatment

I always discuss this risk with patients, particularly those with pre-existing risk factors for diabetes. I recommend:

• Monitoring HbA1c before starting atorvastatin and annually thereafter
• Maintaining a healthy lifestyle with regular exercise and a balanced diet
• Not discontinuing atorvastatin solely because of a modest rise in blood glucose

The NHS information page provides further detail on routine monitoring during statin therapy.

If you are experiencing side effects with atorvastatin, there are several approaches your doctor may consider before abandoning statin therapy altogether.

For mild muscle aches:

• Continue treatment for 4 to 6 weeks to see if symptoms settle
• Ensure thyroid function has been checked (hypothyroidism worsens muscle symptoms)
• Check vitamin D levels, as deficiency can cause similar symptoms
• Consider taking atorvastatin in the morning if evening dosing causes night-time discomfort
• Moderate exercise can paradoxically help with muscle symptoms

Dose reduction:

If symptoms persist, your GP may reduce the dose. Even atorvastatin 10 mg provides meaningful cardiovascular risk reduction.

The NICE cardiovascular risk calculator can help determine the minimum effective dose for your risk profile.

Switching statins:

Different statins have different side effect profiles. Patients intolerant of atorvastatin may tolerate:

• Rosuvastatin (different metabolic pathway)
• Pravastatin (less lipophilic, lower muscle penetration)
• Simvastatin at a lower dose

Alternate-day dosing:

Some specialists use alternate-day or twice-weekly atorvastatin in patients who cannot tolerate daily dosing. While this is off-label, there is evidence supporting its lipid-lowering efficacy.

Non-statin alternatives:

For patients who are truly statin-intolerant (confirmed by rechallenge), NICE recommends ezetimibe as an alternative or add-on therapy.

PCSK9 inhibitors (alirocumab, evolocumab) may be considered for high-risk patients through specialist referral.

The most important message is: do not simply stop your statin without discussing it with your doctor. The cardiovascular protection provided by atorvastatin is substantial and well proven.

While most side effects of atorvastatin are mild, there are situations that require prompt medical attention.

Seek urgent medical advice if you experience:

• Severe, unexplained muscle pain particularly if accompanied by weakness, fever or dark urine (possible rhabdomyolysis)
• Jaundice: yellowing of the skin or whites of the eyes
• Severe abdominal pain: particularly if radiating to the back (rare cases of pancreatitis have been reported)
• Signs of allergic reaction: rash, facial swelling, difficulty breathing
• Unexplained tingling, numbness or burning in hands or feet (peripheral neuropathy is a rare side effect)

Call 999 if you experience:

• Signs of anaphylaxis (severe swelling, breathing difficulty, collapse)
• Very dark or cola-coloured urine with severe muscle weakness (rhabdomyolysis requiring emergency treatment)

Important context:

The serious side effects listed above are rare. In over fifteen years of prescribing atorvastatin, I have seen only a handful of cases of clinically significant myopathy and none of rhabdomyolysis.

The drug has an excellent safety record in millions of patients worldwide.

If you are unsure whether your symptoms are related to atorvastatin, do not stop the medication but contact your GP surgery for advice.

NHS 111 is available around the clock for non-emergency guidance.